The MACH2 study: Role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies

Tore Lind(Skaraborg Hospital), C. Cederberg, L. Zeijlon, Sander Veldhuyzen van Zanten(Victoria General Hospital), Françis Mégraud(Université de Bordeaux), Michael Wrangstadh, Peter Unge(Sandviken Hospital), E. Bayerdörffer(LMU Klinikum), Colm O’Morain(Trinity College Dublin), M. Hellblom, Karna Dev Bardhan(Rotherham General Hospital), Robert E. Spiller(Nottingham University Hospitals NHS Trust)
Gastroenterology
February 1, 1999
10.1016/s0016-5085(99)70119-8
Cited by 433

Related Papers

Functional Bowel Disorders
|Gastroenterology|2006|4.8k
Bowel Disorders
|Gastroenterology|2016|2.8k
Management of <i>Helicobacter pylori</i> infection—the Maastricht IV/ Florence Consensus Report
|Gut|2012|2.3k
Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute <i>Campylobacter</i> enteritis and in post-dysenteric irritable bowel syndrome
|Gut|2000|1.2k
Postinfectious Irritable Bowel Syndrome
|Gastroenterology|2009|1k